Page 1 of 1
MS drug Fampyra receives negative opinion from the CHMP
Posted: Fri Jan 21, 2011 5:04 am
by MSUK
Biogen Idec announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union.
Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.... Read More -
http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
Re: MS drug Fampyra receives negative opinion from the CHMP
Posted: Fri Jan 21, 2011 10:25 am
by scorpion
squiffy2 wrote:
Biogen Idec announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA® (prolonged-release fampridine 10 mg tablets) to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union.
Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.... Read More -
http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310
It just seems that no one can make up their minds about amprya. Usually this means that it is not living up to expectations and will slowly fizzle out!
Walking speed
Posted: Sat Jan 22, 2011 1:11 am
by RuSmolikova
Walking speed is not meaningful benefit for european regulator...
<
shortened url>